Cibus (NASDAQ:CBUS – Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Cibus (NASDAQ:CBUS – Get Free Report) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.04). Cibus had a negative net margin of 14,729.06% and a negative return on equity of 22.70%. The business had revenue of $1.10 million during the quarter, compared to analyst estimates of $0.27 million. On average, analysts expect Cibus to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Cibus Price Performance
Cibus stock opened at $17.06 on Wednesday. Cibus has a 1-year low of $8.90 and a 1-year high of $38.85. The stock has a market cap of $368.84 million, a PE ratio of -0.75 and a beta of 1.99. The stock’s fifty day moving average is $18.51 and its two-hundred day moving average is $16.61.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on CBUS
About Cibus
Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.
Featured Articles
- Five stocks we like better than Cibus
- The How And Why of Investing in Oil Stocks
- Garmin Navigates to New Highs Driven By Wearables Trend
- How is Compound Interest Calculated?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.